Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by n- propylxanthate

Chemical Research in Toxicology

Volumn 12, Issue 4, 1999, Pages 317-322

  Kent, Ute M ^a   Yanev, Stanislav ^a   Hollenberg, Paul F ^a  

^a Medical Science Research Bldg III ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; IODOSOBENZENE; N PROPYLXANTHIC ACID; OXIDIZING AGENT; PENTOXYRESORUFIN DEALKYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; XANTHIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; HALF LIFE TIME; HUMAN; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IODOBENZENES; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; THIONES;

ANIMALIA;

EID: 0032940229     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx9802421     Document Type: Article

References (38)

1. Porter, T. D., and Coon, M. J. (1991) Cytochrome P450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 266, 13469-13472.
2. Gonzalez, F. J. (1988) The molecular biology of cytochrome P450s. Pharm. Rev. 40, 243-288.
3. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, C., and Nebert, D. W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42.
4. Halpert, J. R. (1995) Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol. 35, 29-53.
5. Kedzie, K. M., Baltour, C. A., Escobar, G. Y., Grimm, S. W., He, Y.-A., Pepperl, D. J., Regan, J. W., Stevens, J. C., and Halpert, J. R. (1991) Molecular basis for a functionally unique cytochrome P450IIBI variant. J. Biol. Chem. 266, 22515-22521.
6. Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) High-resolution crystal structure of cytochrome P450 cam. J. Mol. Biol. 195, 687-700.
7. Ravichandran, K. G., Boddupalli, S. S., Hasemann, C. A., Peterson, J. A., and Deisenhofer, J. (1993) Crystal structure of hemoprotein domain of P450 BM-3, a prototype for microsomal P450s. Science 261, 731-736.
8. Hasemann, C. A., Ravichandran, K. G., Peterson, J. A., and Deisenhofer, J. (1994) Crystal structure and refinement of cytochrome P450terp at 2.3 Å resolution. J. Mol. Biol. 236, 1169-1185.
9. Cupp-Vickery, J. R., and Poulos, T. L. (1995) Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nat. Struct. Biol. 2, 144-153.
10. Roberts, E. S., Hopkins, N. E., Alworth, W. L., and Hollenberg, P. F. (1993) Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: Identification of an active site peptide. Chem. Res. Toxicol. 6, 470-479.
11. Roberts, E. S., Hopkins, N. E., Zaluzec, E. J., Gage, D. A., Alworth, W. L., and Hollenberg, P. F. (1995) Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenathrene. Arch. Biochem. Biophys. 323, 295-302.
12. He, K., Falick, A. M., Chen, B., Nilsson, F., and Correia, M. A. (1996) Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 9, 614-622.
13. Rylander, T. M., Hellmold, H., Reihnér, E., Warner, M., and Gustafsson J.-Å. (1997) RT-PCR analysis of cytochrome P450 profile in normal and tumor samples from human breast. FASEB J. 11, P343.
14. Osborne, M. P., Bradlow, H. L., Wong, G. Y., and Telang, T. N. (1993) Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J. Natl. Cancer Inst. 85, 1917-1920.
15. Ekins, S., VandenBranden, M., Ring, B. J., and Wrighton, S. A. (1997) Examination of purported probes of human CYP 2B6. Pharmacogenetics 7, 165-179.
16. Shimada, T., Yamazki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994) Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
17. Madan, A., LeCluyse, E. L., Foster, J., Carroll, K., Lantham, J. D., Yang, D., and Parkinson, A. (1996) Identification and characterization of cytochrome P450 2B6 (CYP2B6) in human liver microsomes and its induction in primary cultures of human hepatocytes. XI International Symposium on Microsomes and Drug Oxidations, UCLA, Los Angeles, CA, July 21-24, 1996, p 203.
18. Yang, T. J., Krausz, K. W., Shou, M., Yang, S. K., Buters, J. T., Gonzalez, F. J., and Gelboin, H. V. (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem. Pharmacol. 55, 1633-1640.
19. McCracken, N. W., Cholerton, S., and Idle, J. R. (1992) Cotinine formation by cDNA-expressed human cytochromes P450. Med. Sci. Res. 20, 877-878.
20. Mimura, M., Baba, T., Yamazaki, H., Ohmori, S., Inui, Y., Gonzalez, F. J., Guengerich, F. P., and Shimada, T. (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056.
21. Styles, J. A., Davies, A., Lim, C. K., DeMatteis, F., Stanley, L. A., White, I. N. H., Yuan, Z.-X., and Smith, L. L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and tormifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15, 5-9.
22. Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J., and Tsutsui, M. (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA expressed human P450s and human liver microsomes, Xenobiotica 26, 681-693.
23. Yamazaki, H., Inoue, K., Mimura, M., Oda, Y., Guengerich, F. P., and Shimada, T. (1996) 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P4501A2 and 2E1 in human liver microsomes. Biochem. Pharmacol. 51, 313-319.
24. Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y., and Funae, Y. (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Biochem. Pharmacol. 51, 1041-1050.
25. Stevens, J. C., White, R. B., Hsu, S. H., and Martinet, M. (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J. Pharmacol. Exp. Ther. 282, 1389-1395.
26. Roberts, E. S., Hopkins, N. E., Foroozesh, M., Alworth, W. L., Halpert, J. R., and Hollenberg, P. F. (1997) Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos. 25, 1242-1248.
27. Yanev, S., Frank, H., Remmer, H., and Stoytchev, T. (1985) Xanthogenates as "suicide" substrates of cyt-P-450. In Cytochrome P450, Biochemistry, Biophysics and Induction (Vereczkey, L., and Magyar, K., Eds.) pp 87-90, Elsevier, New York.
28. Yanev, S., Yanku, I., Stoychev, T., Havilk, I., and Krebs, V. (1982) Effects of potassium ethylxanthogenate and 2,3-dimercaptopropane sulphonate sodium on the pentobarbital pharmacokinetics and metabolism in male mice. Eur. J. Drug Metabol. Pharmacokinet. 7, 21-29.
29. Hadjiolov, D., Frank, M., Hadjiolov, N., and Yanev, S. (1988) Effects of potassium ethylxanthogenate on nitrosodiethylamine-induced DNA damage and on liver carcinogenesis. Arch. Geschwulstforsch. 58, 313-318.
30. Silverman, R. B. (1996) Mechanism-based enzyme inactivators. In Contemporary Enzyme Kinetics and Mechanisms (Purich, D. L., Ed.) pp 291-335, Academic Press, San Diego, CA.
31. Rao, S. R. (1971) Xanthates and related compounds, pp 7-31, Marcel Dekker, New York.
32. Saito, T., and Strobel, H. W. (1981) Purification to homogeneity and characterization of a form of cytochrome P450 with high specificity for benzopyrene from β-naphthoflavone-pretreated rat liver microsomes. J. Biol. Chem. 256, 984-988.
33. Strobel, H. W., and Dignam, J. D. (1978) Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol. 52, 89-92.
34. Hanna, I. H., Teiber, J. F., Kokones, K. L., and Hollenberg, P. F. (1998) Role of alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch. Biochem. Biophys. 350, 324-332.
35. Buters, J. T., Schiller, C. D., and Chou, R. C. (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Biochem. Pharmacol. 46, 1577-1584.
36. Omura, T., and Saito, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemo protein nature. J. Biol. Chem. 239, 2370-2378.
37. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
38. Yamano, S., Nhamburo, P. T., Aoyama, T., Meyer, U. A., Inaba, T., Kalow, W., Gelboin, H. V., McBride, O. W., and Gonzalez, F. J. (1989) cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28, 7340-7348.